Pathogenomix Inc, discovered novel Patho-Seq assay. Patho-Seq uses Next Generation Sequencing for the rapid identifaction of bacteria presented in human sample through dangerous and life-threatening infections.
Patho-Seq detects hundreds of clinically relevant bacteria collected from wide list of clinical conditions and sample types consisting of sepsis from whole blood samples and bacterial meningitis from CSF.
The Patho-Seq test has the ability to advance the treatment of infectious diseases through its targeted 16S sequencing approach. Infections such as sepsis can arise from uncontrolled infections at many sites in the patients body giving rise to massive variety in potentially causative organisms.
One of the major advantages of Next Generation Sequencing is due to the fact that it can rapidly several hundreds of infectious bacteria from a single test without the requirement of specific hypothesis from the clinician regarding the causing of infection.
The traditional culture of intake of sample often reads false negative when patients treated with antimicrobials whereas Patho-Seq asssay can detect bacteria even if the sample is taken after the patient’s treatment.
Existing FDA-approved methods are unable to detect such a breadth of causes with a single test. Patho-Seq's approach has the ability to detect any of hundreds of bacteria.
US Food and Drug Administration (FDA) grants Breakthrough Device Designation for its Patho-Seq assay.